Edgar Filing: Sage Therapeutics, Inc. - Form 4

Sage Therap	peutics, Inc.									
Form 4	2016									
February 10								PPROVAL		
FORM	14 UNITED		URITIES A			GE COMMISSION		3235-0287		
Check th if no lon subject t Section Form 4 c Form 5	ger o STATEN 16. or Filed pur	IENT OF CH	ANGES IN SECUI	BENEF RITIES	ICIAL	Expires: Estimated burden hou	January 31			
obligatic may con <i>See</i> Instr 1(b).	tinue. Section 17(e Utility Hol e Investmen			Act of 1935 or Section of 1940	n			
(Print or Type	Responses)									
1. Name and A IGUCHI K	suer Name an ol 2 Therapeuti		-	Issuer						
(Last)	(First) (I	C C	te of Earliest T	_	,	(Check all applicable)				
C/O SAGE	THERAPEUTIC	(Mon	th/Day/Year) 8/2016			Director Officer (give below) CFO, Sec		6 Owner her (specify asurer		
	(Street)		Amendment, D Month/Day/Yea	-	al	Applicable Line) _X_ Form filed by	d by One Reporting Person			
CAMBRID	GE, MA 02142					Person	More than One R	eporting		
(City)	(State)	(Zip) J	Table I - Non-	Derivative	Securitie	es Acquired, Disposed o	f, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Yea	Code r) (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	Securities I Beneficially (Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	port on a separate line	for each class of	securities bene	ficially ow	ned direct	tly or indirectly.				

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

(Instr. 3)	tr. 3) Price of Derivative Security		(Month/D	ay/Year)	(Instr. 8	0 (1 (1	Acquired r Dispos D) Instr. 3, 4 nd 5)	ed of					
					Code Y	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 28.63	02/08/2016			А	1	15,000		(1)	02/08/2026	Common Stock	15,000	
Reporting Owners													
Reporting Owner Name / Address			Relationships										
			Director	10% Owner Officer						Other			
IGUCHI KIMI C/O SAGE THERAPEUTICS, INC. 215 FIRST STREET CAMBRIDGE, MA 02142				CFO, Secretary and Treasurer									
Signa	tures												
/s/ Erin Lanciani, as Attorney-in-Fact for Kimi Iguchi			02/10/2016										
	**Signature of	f Reporting Person				Date							

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities awarded on 2/08/2016 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option
(1) and Incentive Plan. Options to purchase 3,750 shares of common stock shall vest on the one year anniversary of the Vesting Start Date with 11,250 shares vesting in 36 equal monthly installments thereafter.

Remarks:

Chief Financial Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(